Bank of America
TBPH

Bank of America’s Theravance Biopharma TBPH Stock Holding History

Bank of America’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,100
Closed -$791K – 7249
2017
Q3 		$791K Buy
+23,100
New +$755K ﹤0.01% 4658
2014
Q4 		– Sell
-200
Closed -$5K – 7949
2014
Q3 		$5K Sell
200
-800
-80% -$23.2K ﹤0.01% 7554
2014
Q2 		$32K Buy
+1,000
New +$30.1K ﹤0.01% 6936

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America's TBPH Position: Q2 2026 in Review

Bank of America reduced its Theravance Biopharma (TBPH) stake by 61% in Q2 2026, selling an estimated $1.91M and leaving 73,689 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4506.

Bank of America first reported a position in TBPH in Q2 2014 and has held it in 49 quarters since. The position peaked at $19.3M in Q1 2023. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Bank of America held 73,689 shares of Theravance Biopharma worth $1.25M as of Q2 2026.
  • Bank of America sold 115,466 Theravance Biopharma shares in Q2 2026, an estimated $1.91M.
  • Theravance Biopharma made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #4506 holding.
  • Bank of America first reported a position in Theravance Biopharma in Q2 2014 and has held it in 49 quarters since.
  • Bank of America's Theravance Biopharma position peaked at $19.3M in Q1 2023.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.